NCT00315380Recruiting
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis
Source: ClinicalTrials.gov · Last updated 28 Aug 2026
Brief summary (registry, in English)
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 700 (estimated)
- First submitted
- 14 Apr 2006
- Start date
- 1 Apr 2006
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- University of Pennsylvania
- Diseases
- ANCA-associated vasculitis
- NCT number
- NCT00315380
What you commit to
- Study type: Observational
- Planned participants: 700
- From 1 Apr 2006 to the primary completion date, 31 Dec 2028
- 15 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Inability to give informed consent and to sign the consent form
Who the study is looking for
- Patients with a diagnosis of eosinophilic granulomatosis with polyangiitis are eligible for the study.
- Parent or guardian willing to provide informed consent, if applicable
Sex: All · Does not accept healthy volunteers
Sites (15)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St. Joseph's Healthcare Coordinator of this site? Confirm its status | Hamilton | Canada | Recruiting |
| Mount Sinai Hospital Coordinator of this site? Confirm its status | Toronto | Canada | Completed |
| medius KLINIK KIRCHHEIM Coordinator of this site? Confirm its status | Kirchheim unter Teck | Germany | Recruiting |
| Cambridge University Hospitals NHS Foundation Trust Coordinator of this site? Confirm its status | Cambridge | United Kingdom | Recruiting |
| Guy's and St Thomas' NHS Foundation Trust Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
| Imperial College Healthcare NHS Trust/ Imperial College London Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
| AOU Meyer IRCCS Coordinator of this site? Confirm its status | Florence | Italy | Recruiting |
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Completed |
| Cleveland Clinic Foundation Coordinator of this site? Confirm its status | Cleveland | United States | Completed |
| National Jewish Health Coordinator of this site? Confirm its status | Denver | United States | Completed |
| University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Completed |
| University of Pittsburgh Coordinator of this site? Confirm its status | Pittsburgh | United States | Completed |
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Completed |
| University of Utah Coordinator of this site? Confirm its status | Salt Lake City | United States | Completed |
| University of California San Diego Coordinator of this site? Confirm its status | San Diego | United States | Completed |
Related publications
- Vitamin D status in ANCA-associated vasculitis.Rheumatol Adv Pract · 2023 · PMID 36874269
This page is information, not medical advice. Discuss any trial with your doctor.